Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels

Colorectal cancer (CRC) is a leading cause of cancer mortality. Creatine metabolism was previously shown to critically regulate colon cancer progression. We report that RGX-202, an oral small-molecule SLC6A8 transporter inhibitor, robustly inhibits creatine import in vitro and in vivo, reduces intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurth, Isabel, Yamaguchi, Norihiro, Andreu-Agullo, Celia, Tian, Helen S., Sridhar, Subhasree, Takeda, Shugaku, Gonsalves, Foster C., Loo, Jia Min, Barlas, Afsar, Manova-Todorova, Katia, Busby, Robert, Bendell, Johanna C., Strauss, James, Fakih, Marwan, McRee, Autumn J., Hendifar, Andrew E., Rosen, Lee S., Cercek, Andrea, Wasserman, Robert, Szarek, Michael, Spector, Scott L., Raza, Syed, Tavazoie, Masoud F., Tavazoie, Sohail F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494442/
https://www.ncbi.nlm.nih.gov/pubmed/34613776
http://dx.doi.org/10.1126/sciadv.abi7511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494442/
https://www.ncbi.nlm.nih.gov/pubmed/34613776
http://dx.doi.org/10.1126/sciadv.abi7511

Ejemplares similares